Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes A Randomized Clinical Trial -

Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes A Randomized Clinical Trial
Information type: Randomised controlled trials
Source: Journal of the American Medical Association
Specialities: Diabetes
Summary
Phase II RCT (n=632) reports once-daily oral semaglutide (dose range 2.5 to 40mg od) produced mean change in HbA1c level from baseline to week 26 of −0.7 to −1.9%, -1.9% with sc semaglutide and -0.3% with placebo. This study supports phase III studies to assess clinical outcomes.
UKMi comment

Semaglutide is a human GLP-1 (glucagon-like peptide-1) analogue. A marketing authorisation application for the once-weekly subcutaneous formulation is currently under review with the European Medicines Agency and the US Food and Drug Administration.
Related links: